The global Rituximab Biosimilars market was valued at US$ 2.284 billion in 2023 and is projected to reach US$ 6.065 billion by 2029, at a CAGR of 12.0% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report aims to provide a comprehensive presentation of the global market for Rituximab Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rituximab Biosimilars. This report contains market size and forecasts of Rituximab Biosimilars in global, including the following market information:
- Global Rituximab Biosimilars Market Revenue, 2018-2023, 2024-2030, ($ millions)
- Global Rituximab Biosimilars Market Sales, 2018-2023, 2024-2030, (K Units)
- Global top five Rituximab Biosimilars companies in 2023 (%)
The U.S. Market is Estimated at $ Million in 2023, While China is Forecast to Reach $ Million.
500mg Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Rituximab Biosimilars include Amgen, AryoGen Pharmed, Biocad, Cadila Pharmaceuticals, Celltrion, Dr Reddys Laboratories, Teva, Hetero Group and Innovent Biologics, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Rituximab Biosimilars manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Rituximab Biosimilars Market, by Type, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Rituximab Biosimilars Market Segment Percentages, by Type, 2023 (%)
Global Rituximab Biosimilars Market, by Application, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Rituximab Biosimilars Market Segment Percentages, by Application, 2023 (%)
- Hospital Pharmacy
- Retail Pharmacy
Global Rituximab Biosimilars Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Rituximab Biosimilars Market Segment Percentages, By Region and Country, 2023 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Rituximab Biosimilars revenues in global market, 2018-2023 (Estimated), ($ millions)
- Key companies Rituximab Biosimilars revenues share in global market, 2023 (%)
- Key companies Rituximab Biosimilars sales in global market, 2018-2023 (Estimated), (K Units)
- Key companies Rituximab Biosimilars sales share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Amgen
- AryoGen Pharmed
- Biocad
- Cadila Pharmaceuticals
- Celltrion
- Dr Reddys Laboratories
- Teva
- Hetero Group
- Innovent Biologics
- Intas Biopharmaceuticals
- Mylan
- Probiomed
- TRPharma
- Zenotech Laboratories
Outline of Major Chapters:
Chapter 1: Introduces the definition of Rituximab Biosimilars, market overview.
Chapter 2: Global Rituximab Biosimilars market size in revenue and volume.
Chapter 3: Detailed analysis of Rituximab Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Rituximab Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Rituximab Biosimilars capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
